تحميل
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
1.99 US$
+0.01 US$ · +0.51%
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.
عند الإغلاق
1.99 US$
+0.01 US$ · +0.51%
بعد ساعات التداول
1.98 US$
−0.01 US$ · -0.50%
8 أكتوبر، 4:10 م ET
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.
نطاق اليوم
السعر الحالي 1.99 US$
نطاق 52 أسبوعًا
السعر الحالي 1.99 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
بيع
تقييم
25
مرتفع السعر
المشاعر
48
مختلط
المخاطر
64
مخاطر مرتفعة
الزخم
37
زخم متراجع
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.
نطاق اليوم
السعر الحالي 1.99 US$
نطاق 52 أسبوعًا
السعر الحالي 1.99 US$
أحدث النتائج المعلنة
أحدث النتائج المعلنة
| الإجراء | تاريخ النفاذ | تفاصيل | تاريخ التسجيل | تاريخ الدفع |
|---|---|---|---|---|
تقسيم الأسهم | 25 مارس 2026 | 1:4 | — | — |
تقسيم الأسهم | 24 ديسمبر 2025 | 1:4 | — | — |
تقسيم الأسهم | 10 فبراير 2017 | 1:5 | — | — |
تقسيم الأسهم | 4 أكتوبر 2012 | 1:10 | — | — |
ساري 25 مارس 2026
1:4
ساري 24 ديسمبر 2025
1:4
ساري 10 فبراير 2017
1:5
ساري 4 أكتوبر 2012
1:10
المحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
